These pre-clinical studies demonstrate that PET radiopharmaceuticals can be utilized to detect CTLA-4 expressing immune and tumor cells in vivo; however, further work is needed to determine if this radiopharmaceutical may be an effective agent to monitor response to immunotherapy clinically. This evidence concerns the gene CTLA4 and neoplasm.